You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
SJ 1008030 New
Biological Activity for SJ 1008030
SJ 1008030 is a potent and selective JAK2 Degrader (PROTAC®). This compound shows potent antileukemic efficacy in CRLF2r ALL (Acute Lymphoblastic Leukemia) cell lines (EC50 = 5.4 nM). SJ 1008030 induces dose-dependent JAK2 degradation (IC50 = 32.05 nM) in xenograft models of kinase-driven ALL, with no effect on GSPT1 levels.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Sold under license from St. Jude Children's Research Hospital
Technical Data for SJ 1008030
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for SJ 1008030
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for SJ 1008030
The following data is based on the product molecular weight 987.97. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||2.02 mL||10.12 mL||20.24 mL|
|2.5 mM||0.4 mL||2.02 mL||4.05 mL|
|5 mM||0.2 mL||1.01 mL||2.02 mL|
|25 mM||0.04 mL||0.2 mL||0.4 mL|
References for SJ 1008030
References are publications that support the biological activity of the product.
Chang et al (2021) Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia. Blood 138 2313 PMID: 34110416
Constantinescu et al (2021) Degrading JAK2 in ALL by ruxolitinib-based PROTACs. Blood 138 2301 PMID: 34882211
If you know of a relevant reference for SJ 1008030, please let us know.
View Related Products by Target
Keywords: SJ 1008030, SJ 1008030 supplier, SJ1008030, protacs, active, degraders, selective, JAK2, kinases, degrades, proteolysis, targeting, chimeras, PROTAC, PROTACS, targeted, protein, degradation, tpd, baricitinib, Active, Degraders, JAK, 7675, Tocris Bioscience
Citations for SJ 1008030
Citations are publications that use Tocris products.
Currently there are no citations for SJ 1008030. Do you know of a great paper that uses SJ 1008030 from Tocris? Please let us know.
Reviews for SJ 1008030
There are currently no reviews for this product. Be the first to review SJ 1008030 and earn rewards!
Have you used SJ 1008030?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Targeted Protein Degradation Research Product Guide
This brochure highlights the tools and services available from Bio-Techne to support Targeted Protein Degradation research, including:
- Active Degraders
- TAG Degradation Platform
- Degrader Building Blocks
- Custom Degrader Services
- Ubiquitin-Proteasome System Proteins and Assays
- Assays for Protein Degradation
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics in Cancer Poster
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Targeted Protein Degradation Poster
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia